April 24, 2023 : Endpoints News - FDA lifts nearly two-year hold on MaaT Pharma's microbiome therapy, opens door to PhIII - MaaT Pharma

To read the article, click here!

Previous PostApril 25, 2023: BioPharma Reporter - FDA lifts 18-month clinical hold on MaaT Pharma's microbiome therapeutic
Next PostApril 24, 2023: The Pharma Letter - FDA lifts clinical hold of MaaT Pharma's lead microbiome therapeutic trial

© 2025 MaaT Pharma. MaaT Pharma’s mission is to restore microbiome function to treat life-threatening diseases

MaaT Pharma dans les médias MaaT Pharma in the News Devenez membre du club Become a member of the club